文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Temozolomide resistance in glioblastoma multiforme.

作者信息

Lee Sang Y

机构信息

Department of Neurosurgery, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.

出版信息

Genes Dis. 2016 May 11;3(3):198-210. doi: 10.1016/j.gendis.2016.04.007. eCollection 2016 Sep.

DOI:10.1016/j.gendis.2016.04.007
PMID:30258889
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6150109/
Abstract

Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily to the over-expression of O-methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been developed for use in experiments designed to define the mechanism of TMZ resistance and the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive TMZ resistant GBM cells have not been systemically compared. This article reviews the characteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell lines. It also summarizes potential treatment options for TMZ resistant GBMs.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3547/6150109/661d8c5a5b92/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3547/6150109/661d8c5a5b92/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3547/6150109/661d8c5a5b92/gr1.jpg

相似文献

[1]
Temozolomide resistance in glioblastoma multiforme.

Genes Dis. 2016-5-11

[2]
Temozolomide: mechanisms of action, repair and resistance.

Curr Mol Pharmacol. 2012-1

[3]
Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.

Cancer Res. 2011-3-15

[4]
PARP inhibition suppresses the emergence of temozolomide resistance in a model system.

J Neurooncol. 2020-7

[5]
Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair.

Oncology. 2011-7-1

[6]
Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway.

Phytomedicine. 2022-5

[7]
Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.

J Neurosurg. 2016-5-13

[8]
Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase.

Cancers (Basel). 2022-7-22

[9]
Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.

Clin Cancer Res. 2020-4-1

[10]
Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.

Clin Cancer Res. 1999-10

引用本文的文献

[1]
Demethoxycurcumin induces apoptosis and reduces cell migration by affecting AKT/mTOR-dependent autophagy in human glioma U87MG and T98G cell lines.

Mol Biol Rep. 2025-9-8

[2]
The Role of Pyk2 Kinase in Glioblastoma Progression and Therapeutic Targeting.

Cancers (Basel). 2025-8-9

[3]
Ferroptosis as a therapeutic target in glioblastoma: Mechanisms and emerging strategies.

Mol Ther Nucleic Acids. 2025-7-30

[4]
GLUT3 enhances chemosensitivity in glioblastoma by transporting temozolomide and capecitabine.

Cell Death Discov. 2025-8-14

[5]
Inhibition of FOXM1 Leads to Suppression of Cell Proliferation, Migration, and Invasion Through AXL/eEF2 Kinase Signaling and Induces Apoptosis and Ferroptosis in GBM Cells.

Int J Mol Sci. 2025-7-15

[6]
In Vivo and In Vitro Experimental Study Comparing the Effect of a Combination of Sodium Dichloroacetate and Valproic Acid with That of Temozolomide on Adult Glioblastoma.

Int J Mol Sci. 2025-7-15

[7]
High-throughput impedance monitoring in 3D tumor cultures: a multiplex, microfluidic-free platform for drug screening.

Lab Chip. 2025-7-28

[8]
Synthetic oleanolic acid derivative, RTA-408, overcome in TMZ-resistant glioblastoma cells by inducing apoptosis and G1 cell cycle arrest.

Med Oncol. 2025-7-20

[9]
Hydrogel microdroplet based glioblastoma drug screening platform.

bioRxiv. 2025-7-12

[10]
A Pharmacologic Approach Against Glioblastoma-A Synergistic Combination of a Quinoxaline-Based and a PI3K/mTOR Dual Inhibitor.

Int J Mol Sci. 2025-7-2

本文引用的文献

[1]
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.

Cell Cycle. 2015

[2]
APE1/REF-1 down-regulation enhances the cytotoxic effects of temozolomide in a resistant glioblastoma cell line.

Mutat Res Genet Toxicol Environ Mutagen. 2015-11

[3]
Augmentation of invadopodia formation in temozolomide-resistant or adopted glioma is regulated by c-Jun terminal kinase-paxillin axis.

Biochem Biophys Res Commun. 2015

[4]
Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics.

J Neurooncol. 2015-10

[5]
NF-κB inhibitor reverses temozolomide resistance in human glioma TR/U251 cells.

Oncol Lett. 2015-6

[6]
Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.

Cancer Res. 2015-8-1

[7]
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.

BMC Cancer. 2015-4-11

[8]
Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.

J Neurooncol. 2015-1

[9]
Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.

Clin Cancer Res. 2014-7-30

[10]
The medicinal chemistry of imidazotetrazine prodrugs.

Pharmaceuticals (Basel). 2014-7-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索